HLSQ logo

TESSERA DEFENSE AND HOMELAND

HLSQNYSE AMERICAN
🏆 #5392 by market capEarnings Nov 11US Equity
$83.51▲ $5.67 (+6.79%)
Simulated price
🔔
Track HLSQ
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 6.8%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$1M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
44
Weak
No chart data available for HLSQ.

Trading Snapshot

Day Range
$82.21 – $85.16
52-Week Range
$0.44 – $2.16
Volume
$3.27B
Avg Volume
$3.42B
Shares Outstanding
2.7M
Next Earnings
Oct 22, 2026

Fundamentals Snapshot

Annual Revenue
$83,143
Last Q Revenue
$19,448
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
—
Dividend Yield
—

Why Investors Own HLSQ

  • ✓High-growth profile — revenue up -7.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 65% gross margin and 15% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

HLSQ logo

TESSERA DEFENSE AND HOMELAND

HLSQ
Financial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$83,143▼ −7.8% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
64.9%▲ +1.7% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$7,233▼ −7.8% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$12,388▼ −7.8% YoY
StockOtter · stockotter.space

About TESSERA DEFENSE AND HOMELAND

Tessera Defense & Homeland Security, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. The company was founded in March 2015 and is headquartered in Dover, DE.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
44/100

Analyst Price Target

ⓘ
Average Target
$100.71
▲ +20.6% Upside
High Target$118.09
Low Target$89.63
Based on 35 analysts

Latest News & Updates

🚀
Reuters·2h ago

TESSERA DEFENSE AND HOMELAND tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift HLSQ price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

TESSERA DEFENSE AND HOMELAND announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.